See more : T.C.J. Asia Public Company Limited (TCJ.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Invitae Corporation (NVTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invitae Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Consumer Automotive Finance, Inc. (NWAU) Income Statement Analysis – Financial Results
- Enel Chile S.A. (ENIC) Income Statement Analysis – Financial Results
- INTEGRATED INDUSTRIES LIMITED (IIL.BO) Income Statement Analysis – Financial Results
- Adams Natural Resources Fund, Inc. (PEO) Income Statement Analysis – Financial Results
- The Limestone Boat Company Limited (LMSBF) Income Statement Analysis – Financial Results
Invitae Corporation (NVTA)
About Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.30M | 460.45M | 279.60M | 216.82M | 147.70M | 68.22M | 25.05M | 8.38M | 1.60M | 148.00K | 0.00 |
| Cost of Revenue | 417.26M | 348.67M | 198.28M | 118.10M | 80.11M | 50.14M | 27.88M | 16.52M | 5.62M | 667.00K | 0.00 |
| Gross Profit | 99.05M | 111.78M | 81.32M | 98.72M | 67.59M | 18.08M | -2.83M | -8.15M | -4.02M | -519.00K | 0.00 |
| Gross Profit Ratio | 19.18% | 24.28% | 29.09% | 45.53% | 45.76% | 26.50% | -11.30% | -97.22% | -250.62% | -350.68% | 0.00% |
| Research & Development | 402.09M | 416.09M | 240.61M | 141.53M | 63.50M | 46.47M | 44.63M | 42.81M | 22.14M | 16.04M | 5.56M |
| General & Administrative | 192.31M | 248.07M | 324.57M | 79.07M | 52.23M | 39.47M | 24.09M | 16.05M | 12.61M | 5.76M | 3.00M |
| Selling & Marketing | 218.88M | 225.91M | 168.32M | 122.24M | 74.43M | 53.42M | 28.64M | 22.48M | 8.76M | 2.43M | 0.00 |
| SG&A | 411.20M | 473.98M | 492.89M | 201.31M | 126.66M | 92.89M | 52.72M | 38.53M | 21.37M | 8.20M | 3.00M |
| Other Expenses | 8.05M | 25.68M | -32.33M | -3.89M | -2.57M | -303.00K | 348.00K | -94.00K | -79.00K | -26.00K | 2.00K |
| Operating Expenses | 813.28M | 890.07M | 733.50M | 342.83M | 190.15M | 139.36M | 97.35M | 81.33M | 43.51M | 24.23M | 8.56M |
| Cost & Expenses | 1.23B | 1.24B | 931.77M | 460.94M | 270.26M | 189.50M | 125.23M | 97.86M | 49.13M | 24.90M | 8.56M |
| Interest Income | 56.75M | 49.90M | 29.77M | 12.41M | 0.00 | 0.00 | 0.00 | 211.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 56.75M | 49.90M | 29.77M | 12.41M | 7.03M | 3.65M | 421.00K | 0.00 | 61.00K | 59.00K | 43.00K |
| Depreciation & Amortization | 150.13M | 106.15M | 6.72M | 12.32M | 13.54M | 9.18M | 6.55M | 5.32M | 2.32M | 928.00K | 277.00K |
| EBITDA | -3.12B | -391.64M | -652.17M | -244.11M | -111.59M | -121.58M | -93.63M | -89.48M | -45.19M | -23.85M | -8.28M |
| EBITDA Ratio | -109.26% | -145.97% | -230.85% | -106.91% | -75.55% | -178.22% | -398.57% | -1,068.00% | -2,968.02% | -16,115.54% | 0.00% |
| Operating Income | -714.24M | -778.29M | -652.17M | -244.11M | -122.56M | -121.28M | -100.18M | -89.48M | -47.53M | -24.75M | -8.56M |
| Operating Income Ratio | -138.34% | -169.03% | -233.25% | -112.59% | -82.98% | -177.77% | -399.96% | -1,068.00% | -2,963.09% | -16,725.00% | 0.00% |
| Total Other Income/Expenses | -2.44B | 362.42M | -62.10M | -16.30M | -9.60M | -3.96M | -73.00K | -305.00K | 36.00K | -85.00K | -41.00K |
| Income Before Tax | -3.15B | -415.86M | -714.27M | -260.42M | -132.16M | -125.24M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Income Before Tax Ratio | -610.34% | -90.32% | -255.46% | -120.10% | -89.48% | -183.57% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| Income Tax Expense | -44.90M | -36.86M | -105.40M | -18.45M | -2.80M | -1.86M | -5.78M | -5.11M | -2.33M | 33.00K | 45.00K |
| Net Income | -3.11B | -379.01M | -608.87M | -241.97M | -129.36M | -123.38M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Net Income Ratio | -601.64% | -82.31% | -217.77% | -111.60% | -87.58% | -180.85% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| EPS | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| EPS Diluted | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| Weighted Avg Shares Out | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
| Weighted Avg Shares Out (Dil) | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
– Announcing Invitae Generation™, a high-quality variant detection and classification platform – SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College...
Genetic test maker Invitae files for bankruptcy protection in US
Softbank-backed genetic test maker Invitae said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy court and intends to pursue a sale process.
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
– Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients – SAN FRANCISCO , Feb. 13, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, announced...
The New York Stock Exchange Will Start Delisting Invitae (NVTA) Stock
Yesterday, shares of Invitae (NYSE: NVTA ) stock plummeted lower by over 75% after The Wall Street Journal reported that the genetic testing services company was preparing for bankruptcy. Invitae has hired advisors Kirkland & Ellis, Moelis & Company, and...
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy
Invitae (NYSE: NVTA ) stock fell as much as 78% yesterday before it was ultimately halted because undisclosed news about the firm was pending. Many investors now expect that the SoftBank (OTCMKTS: SFTBY ) backed genetic testing specialist will file...
Why Is Invitae (NVTA) Stock Down 75% Today?
Medical genetics firm Invitae (NYSE: NVTA ) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — leveraging genetic testing and diagnostics to assess hereditary disease risks...
Medical test maker Invitae prepares for bankruptcy - WSJ
Medical test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported on Monday, according to people familiar with the matter.
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based...
Is Invitae Stock a Buy Now?
Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges.
Invitae Completes Sale of Reproductive Health Assets to Natera
SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA). The...
Source: https://incomestatements.info
Category: Stock Reports